Latanoprost Biogaran

Latanoprost, the active ingredient in Latanoprost Biogaran, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with primary open‑angle glaucoma and ocular hypertension, helping to preserve visual function.

GNH USA supplies Latanoprost Biogaran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU regulatory standards and is manufactured under strict quality‑assured processes.

Latanoprost is used in the management of glaucoma and ocular hypertension by enhancing aqueous humor outflow.

- Primary open‑angle glaucoma: reduces intra‑ocular pressure to help preserve the visual field. - Ocular hypertension: lowers intra‑ocular pressure, decreasing the risk of progression to glaucoma. - Secondary open‑angle glaucoma (e.g., pseudoexfoliative): improves uveoscleral outflow to control pressure.

Latanoprost may cause ocular and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness (hyperemia) - Increased eyelash length and density - Darkening of the iris pigment - Eye irritation or foreign‑body sensation - Blurred vision - Periocular skin hyperpigmentation

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema) - Uveitis or iritis - Macular edema - Paradoxical increase in intra‑ocular pressure - Corneal thinning or ulceration - Vision loss

When prescribing Latanoprost, clinicians should consider several safety and handling measures.

- Monitor intra‑ocular pressure: assess IOP regularly after initiation. - Assess for ocular infections: avoid use in active conjunctivitis or keratitis. - Use with caution in patients with a history of uveitis: may exacerbate inflammation. - Avoid in individuals with known hypersensitivity to prostaglandin analogues. - Evaluate iris colour changes: inform patients about possible permanent darkening. - Store at room temperature: keep bottle tightly closed, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents, influencing efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other prostaglandin analogues (e.g., bimatoprost): risk of excessive IOP reduction. - Simultaneous administration of ocular carbonic anhydrase inhibitors: may cause additive pressure‑lowering effect. - Use with ocular corticosteroids in susceptible patients: increased risk of cataract formation.

Moderate Interactions (Monitor Closely): - Topical beta‑blockers (e.g., timolol): monitor for additive IOP lowering. - Alpha‑agonist eye drops (e.g., brimonidine): observe for enhanced hypotensive effect. - Systemic antihypertensive drugs: watch for systemic blood pressure changes in sensitive individuals. - Non‑steroidal anti‑inflammatory eye drops: may diminish Latanoprost efficacy.